

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Link-Asia International MedTech Group Limited (the “**Company**”) hereby announces the following change in the Company:

#### **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Link-Asia International MedTech Group Limited together with its subsidiaries (the “**Group**”) hereby announces, Mr. Liu Zhiwei (“**Mr. Liu**”) has been appointed as an executive Director of the Company with effect from 1 November 2022. The biographical details of Mr. Liu are set out below:

#### **Mr. Liu Zhiwei (劉志威)**

Mr. Liu, aged 53, obtained a Specialist Certificate of General Higher Education in Clinical Medicine from Sun Yat-sen University of Medical Sciences in 1992, a Bachelor’s Degree in Clinical Medicine in Chinese and Western Medicine from Hunan University of Chinese Medicine in 2015 and an EMBA degree from Jilin University in 2017. In addition, Mr. Liu is currently an executive vice president of the Meixian Chamber of Commerce in the PRC. Prior to joining the Group, he was the chairman of Shenzhen Xinxin Medical Technology Development Co.,Ltd.\* (深圳市新鑫醫療科技發展有限公司) and the chairman of Yuanta Chinese Medicine Chain (Shenzhen) Co., Ltd. Mr. Liu has over 30 years of experience in Chinese medical business and over 20 years of experience in the operation and management of Chinese medicine healthcare institutions. He also has solid theoretical knowledge in the field of Chinese medicine technology and health preservation by food.

Mr. Liu will enter into a service agreement as an executive Director with the Company for an initial term of three years, and will be subject to retirement by rotation and re-election at general meeting of the Company in accordance with the Company's articles of association. Mr. Liu is entitled to the remuneration of HK\$1 million per annum as specified in his service agreement and discretionary bonus, which is determined by the Board (the decision of which was based on the recommendation of the remuneration committee) with reference to his duties and responsibilities in the Company, the prevailing market rate and the remuneration policy of the Company. Such remuneration is subject to review by the remuneration committee and the Board from time to time. As a Director, Mr. Liu is subject to retirement by rotation and re-election in accordance with the Company's articles of association.

Save as disclosed above, as at the date of this announcement, Mr. Liu: (i) does not hold any other positions with the Company or other members of the Group; (ii) does not have any relationships with any Directors, senior management or substantial or controlling shareholders (as respectively defined in the Rules Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; (iii) has not at any time during the three years preceding the date of this announcement served nor is currently serving as a director of any other publicly listed companies in Hong Kong or overseas; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there is no other information to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules (particularly in relation to subparagraphs (h) to (v) therein) nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to the appointment of Mr. Liu.

The Board would like to take this opportunity to welcome Mr. Liu on joining the Board.

By order of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and executive Director*

Hong Kong, 1 November 2022

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Liu Zhiwei and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.*

\* *For identification purposes only*